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Abstract
Curdlan sulfate (CRDS), a sulfated 1R3-b-D glucan, previously shown to be a potent HIV entry inhibitor, is characterized in
this study as a potent inhibitor of the Dengue virus (DENV). CRDS was identified by in silico blind docking studies to exhibit
binding potential to the envelope (E) protein of the DENV. CRDS was shown to inhibit the DENV replication very efficiently
in different cells in vitro. Minimal effective concentration of CRDS was as low as 0.1 mg/mL in LLC-MK2 cells, and toxicity was
observed only at concentrations over 10 mg/mL. CRDS can also inhibit DENV-1, 3, and 4 efficiently. CRDS did not inhibit the
replication of DENV subgenomic replicon. Time of addition experiments demonstrated that the compound not only
inhibited viral infection at the host cell binding step, but also at an early post-attachment step of entry (membrane fusion).
The direct binding of CRDS to DENV was suggested by an evident reduction in the viral titers after interaction of the virus
with CRDS following an ultrafiltration device separation, as well as after virus adsorption to an alkyl CRDS-coated membrane
filter. The electron microscopic features also showed that CRDS interacted directly with the viral envelope, and caused
changes to the viral surface. CRDS also potently inhibited DENV infection in DC-SIGN expressing cells as well as the
antibody-dependent enhancement of DENV-2 infection. Based on these data, a probable binding model of CRDS to DENV E
protein was constructed by a flexible receptor and ligand docking study. The binding site of CRDS was predicted to be at
the interface between domains II and III of E protein dimer, which is unique to this compound, and is apparently different
from the b-OG binding site. Since CRDS has already been tested in humans without serious side effects, its clinical
application can be considered.
Citation: Ichiyama K, Gopala Reddy SB, Zhang LF, Chin WX, Muschin T, et al. (2013) Sulfated Polysaccharide, Curdlan Sulfate, Efficiently Prevents Entry/Fusion and
Restricts Antibody-Dependent Enhancement of Dengue Virus Infection In Vitro: A Possible Candidate for Clinical Application. PLoS Negl Trop Dis 7(4): e2188.
doi:10.1371/journal.pntd.0002188
Editor: Scott F. Michael, Florida Gulf Coast University, United States of America
Received August 31, 2012; Accepted March 20, 2013; Published April 25, 2013
Copyright:  2013 Ichiyama et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by NUS SoM Start-up Grant (R-182-000-160-733, R-182-000-160-133) to NY. The funders had no role in study design, data
collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: micny@nus.edu.sg
. These authors contributed equally to this work.
Introduction
Globally, an estimated 50–100 million people are infected with
DENV each year [1]. Dengue is the most important mosquito-
transmitted viral disease in the world, particularly in the tropical
and subtropical countries [2,3]. The virus is transmitted to humans
via the mosquito vectors, Aedes aegypti and Aedes albopictus. There are
four antigenically distinct serotypes of DENV, DENV-1 to
DENV-4 [1]. All serotypes cause a range of human diseases,
ranging from mild dengue fever (DF) to dengue hemorrhagic fever
(DHF) and dengue shock syndrome (DSS), which can be fatal [4].
Primary infection by the virus induces immunity against the
infecting serotype. However, a secondary infection with a different
serotype has been shown to enhance the risk of developing DHF/
DSS, a phenomenon termed antibody-dependent enhancement
(ADE) [5].
Dengue virus binds to, and enters, a permissive host cell via
uncharacterized receptors, undergoing receptor–mediated endo-
cytosis. Upon acidification of the endocytic vesicle, viral and
vesicular membranes fuse, allowing entry of the nucleocapsid into
the host cytoplasm. The viral RNA is uncoated and released in the
cytoplasm and it is directly accessible for translation. Virus
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assembly occurs in the endoplasmic reticulum, and upon
maturation of the virions transported in secretory vesicles, using
the Golgi network, mature viruses are released from the cell [6].
This multi-step DENV infection cycle presents potential drug
targets during entry, viral membrane fusion, translation, assembly,
and maturation. Traditionally, antiviral agents designed against
Flaviviruses have focused on the non-structural proteins required
for viral RNA replication, specifically, inhibition of essential
enzymes like NS3 protease and NS5 RNA-dependent RNA
polymerase [7–10]. However, recent advances in the X-ray
crystallographic and electron microscopic analysis of the DENV
structure and its component proteins have led to the identification
of other potential targets for drug development [11–13]. The E
protein has emerged, due to such studies, as a promising target for
the inhibition of virus entry into cells [14–20]. The DENV-2 E
protein is a class II viral fusion protein, consisting of three
domains: domain I is the central structure, domain II is the
dimerization domain containing the fusion peptide, and domain
III has the putative receptor-binding site. Crystal structures of the
DENV E protein at different stages of virus life cycle reveal that
the protein exists in different conformations and states of
polymerization, brought about by domain rearrangements, in
the mature, immature and the post-fusion stages [21]. Structural
studies of the E protein by Modis et al. [13] revealed a
hydrophobic pocket near the hinge region between domains I
and II which was found to accommodate a molecule of the
detergent N-octyl-beta-d-glucoside (bOG). These studies have
provided impetus for antiviral drug development targeting the
viral entry process.
The anti-HIV effect of CRDS was first discovered based on our
observation that several sulfated polysaccharides, dextran, xylofur-
anan, and ribofuranan, but not their non-sulfated counterparts,
completely prevented HIV-induced cytopathic effects with very
high selectivity indices [22–23]. CRDS, with its branched b-d-
(1R3) glucan backbone with piperidine-N-sulfonic acid, consists of
molecules with various molecular masses and degrees of sulfation.
We showed that the anti-HIV activity of CRDS was positively
correlated with its molecular weight [23]. The anti-coagulant
activity of CRDS was significantly lower than that of standard
dextran sulfate and heparin [24]. CRDS was thus expected to
have potential as an AIDS drug through inhibition of virus entry
in the early stage of infection. CRDS has also been shown to be
effective against Plasmodium falciparum in vitro [25]. Accordingly,
Phase I trial of CRDS against HIV infection and Phase II trial
against severe/cerebral Plasmodium falciparum malaria had been
performed in the US and in Thailand and South Africa,
respectively. The results showed that the treatment was well
tolerated by the patients and it showed some clinical benefits [26].
In the present study, based on a preliminary in silico blind
docking study which indicated that CRDS could be a probable
inhibitor of the DENV E protein, we have characterized its
inhibitory activity through a cell-based anti-DENV screening
effort and identified that this polysaccharide can block DENV at
both the binding and fusion steps very efficiently. Our in silico
docking model indicates that the compound binds to a pocket on
the DENV E protein. CRDS shows a favorable selectivity index
against all serotypes of DENV. Since the compound has already
been tested in humans without serious side effects, it provides a
possibility for clinical application.
Materials and Methods
Blind docking study of CRDS with DENV E protein
The coordinates of the DENV E protein were obtained from
PDB from the crystal structure 1OKE [13]. The crystal structure
details the E protein in its dimeric pre-fusion conformation. For
the purpose of the study, the crystal structure was modified by the
Protein Preparation Wizard module of Schrodinger Suite 2012
(Schrodinger).
The binding site identification of the CRDS in the E protein
was performed by the blind docking method using the Molegro
Virtual Docker (MVD) program (Molegro). Overlapping grids of
30 A˚ radius were used to define the search space on the E protein.
The grid based MolDock scoring function was used to define the
energy terms to rank the potential binding sites [27]. The
MolDock Simplex evolution algorithm was chosen for the
prediction. A population size of 50, with 1500 maximum iterations
was used over ten runs per grid. The simplex minimization
procedure was performed with 300 iterations, and the neighbor
distance factor set to 1.00. For pose generation, the energy
threshold was set to 100 [27].
Binding conformation determination of CRDS on DENV E
protein
The Induced Fit module of Schrodinger Suite 2012 (Schro-
dinger) was used to predict the best binding pose of the E protein,
taking into account the conformational changes induced by the
binding of the CRDS molecule [28]. The blind docking procedure
employed to predict the binding pocket predicted that the CRDS
might form strong H-bonding interactions with Arg2. Based on
these results, the search grid was constructed around Arg2 of one
of the two chains of the E protein, the size set to 26 A˚ around each
side of the residue. The binding pocket predicted by the blind
docking procedure was used as the search space. Docking was
done by allowing receptor flexibility to account for the conforma-
tional changes induced upon ligand binding. The ligand too was
docked flexibly to sample all possible conformations of the ligand
due to torsions about the rotatable bonds. The van der Waals radii
for both the receptor and ligand were scaled by a factor of 0.50.
Residues within 5 A˚ of the docked ligand were subjected to
refinement [29–31].
The root mean square deviation of the best docked pose of the E
protein, as determined by Induced Fit with CRDS, from its crystal
structure conformation (pre-fusion) was determined using the
rmsd.py script (Schrodinger Suite 2012 script collection). The
Author Summary
There is no specific approved antiviral and vaccine for
treatment or prevention of dengue, an acute mosquito-
transmitted viral disease that affects more than 50 million
people each year. Dengue virus (DENV) entry is a critical
step that establishes the infection and enables virus
replication. Curdlan sulfate (CRDS) is known to inhibit
the entry and propagation of HIV-1 in the laboratory. Here
we applied a computational binding site identification
strategy, which suggested that CRDS could be a probable
entry inhibitor of the viral surface E protein. CRDS potently
blocked DENV infection at an early stage of the virus
lifecycle in vitro. In addition, CRDS prevented antibody
dependent enhancement, which is considered to be one
of the most important clinical observations in DENV-
infected patients. CRDS shows a favorable selectivity index
against all serotypes of DENV. Further computational
docking indicates that the compound binds to a pocket
on the DENV E protein. Since CRDS has already been
tested in humans without serious side effects, it can be a
good candidate for clinical application.
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RMSD per individual residue was determined using the rmsd_by_
residue script of Schrodinger Suite 2012 script collection.
Cells
LLC-MK2 cells were grown in Eagle’s minimum essential
medium (EMEM)(SIGMA, St. Louis, MO) supplemented with
10% fetal bovine serum (FBS) (Invitrogen, Carlsbad, CA) with
penicillin and streptomycin. HL-60, THP-1 and Raji-DC-SIGN
cells were maintained in RPMI 1640 (Invitrogen, Carlsbad, CA)
containing 10% FBS, and incubated at 37uC in 5% CO2. Aedes
albopictus C6/36 cells were maintained in RPMI-1640 medium
with 25 mM HEPES supplemented with 8% FBS and incubated
at 28uC. A549 replicon cells (containing DENV-2 NS genes) were
grown as described elsewhere [32].
Viruses
Clinical samples of DENV-1 and DENV-4 and laboratory-
adapted New Guinea C (NGC) strain of DENV-2 were kindly
provided by Dr. Justin JH Chu (National University of Singapore,
Singapore). DENV-3 strain EDEN8630K1 was isolated by EEO
[33]. These viruses were propagated in C3/36 cells grown in
RPMI-1640 medium supplemented with 25 mM HEPES, 8%
FBS and antibiotics. The supernatant from infected cells was
centrifuged to remove cell debris, then aliquoted and stored at
280uC.
For virus concentration, supernatant from DENV-infected cell
cultures was loaded onto a 30% (wt/wt) sucrose cushion and
centrifuged for 16 h at 100,0006 g at 4uC.
The virus fraction obtained was re-suspended in PBS.
Chemicals and synthesis of CRDS and its analogues
CRDS was obtained through one of the authors (TY) from the
Ajinomoto Co Inc., Tokyo, Japan [average molecular mass,
41 kDa; sulfur content, 11.5% (wt/wt)] (Fig. 1A) and was dissolved
in sterile phosphate-buffered saline (PBS) [22–24,34]. To synthe-
size CRDS analogues, commercial Curdlan (M, = 8.96104, Wako
Pure Chemical Industries, Tokyo), pyridine-SO3 complex (SO3-
pyridine) (Tokyo Chemical Industry, Tokyo), and dry Me2SO
(Aldrich Chemical, Milwaukee, WI) were used without further
purification. Piperidine-N-sulfonic acid was prepared from piper-
idine and chlorosulfonic acid according to the method of
Nagasawa et al. [34,35]
Plaque forming assay
Tenfold serial dilutions of virus were added to LLC-MK2 cells
in 6-well plates, followed by 1 h incubation at 37uC with gentle
shaking every 15 min. The medium was aspirated and replaced
with 0.8% methylcellulose (CALBIOCHEM, San Diego, CA) in
maintenance medium (EMEM, 10% FBS, penicillin and strepto-
mycin). At 5 days post-inoculation, cells were fixed with 4%
paraformaldehyde in PBS at room temperature for 20 min. Next,
they were washed with water before the addition of 1 mL 1%
crystal violet at room temperature for 20 min. The plates were
then washed and dried, and the plaque forming units per milliliter
(pfu/mL) were calculated.
Antiviral activity based on cytotoxicity assays
Anti-dengue virus activity and cytotoxicity in LLC-MK2 cells
were monitored by infecting the cells with DENV. Infected and
non-infected cells were exposed to a range of concentrations of test
compounds, after which, the LLC-MK2 cells were allowed to
proliferate for 5 days, and the number of viable cells was
quantified by the 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetra-
zolium bromide (MTT) (SIGMA, St. Louis, MO) method in 96-
well plates [36,37].
Replicon luciferase assay
A549 cells containing a luciferase-reporting replicon of DENV-
2 were seeded at a cell density of 256104 cells/well in 6-well plates
[31]. The cells were treated with 100 mg/mL of heparin, 100 mg/
mL of CRDS, or medium with DMSO. After incubation for 48 h
at 37uC with 5% CO2, luciferase activity was measured using the
Renilla luciferase assay system (Promega, Madison, WI). Results
were normalized by protein quantity.
Binding assay
Cells (LLC-MK2, HL-60, and THP-1) were incubated with
DENV-2 at 37uC for 1.5 h to allow viral adsorption in the
presence or absence of CRDS. The cells were then thoroughly
washed and cultured for 4 more days and viral antigen expression
was analyzed by FACS analysis as described below.
Separation of DENV by ultrafiltration and its titration
following DENV-CRDS interaction
The viral samples (5.06106 pfu/mL) were directly mixed with
CRDS (500 mg/mL) at 4uC for 1 h followed by filtration through
a Vivaspin 500, 100 kDa molecular weight cut off (GE
Healthcare, Buckinghamshire, UK) to separate the DENV. The
DENV titers were monitored by a plaque assay as described
previously.
DENV titration after virus adsorption to an alkyl CRDS-
coated membrane filter
The alkyl CRDS-coated membrane filter was prepared as
described by Muschin et al. [38]. Briefly, before preparation, the
weight of the nitrocellulose membrane filter was measured
precisely by a Mettler microbalance instrument. The average
weight of 10 filters was used. A 1% aqueous solution (2 mL) of
alkyl CRDS with a degree of alkylation (DOA) of 0.03 was passed
slowly through the nitrocellulose membrane filter in the holder by
a syringe and dried overnight under vacuum below 40uC to give
an alkyl CRDS-coated membrane. The amount of fixed CRDS on
the membrane filter was determined by weighing to be around
2.0 mg. Concentrated virus was incubated with the membrane
with or without alkyl CRDS for 5 min at 4uC, and then viral titers
were monitored by a plaque assay as described previously.
Electron microscopy (EM)
Dengue virus with a titer of 16107 pfu was diluted in 10 mM
HEPES (SIGMA, St. Louis, MO) buffer to a final concentration of
76105 pfu which was used for analyzing the virus-compound
interaction. These solutions were incubated separately on 0.01%
poly-l-lysine coated 300 carbon nickel grid for 1 min. After fixing
the samples with 1% Glutaraldehyde (SIGMA, St. Louis, MO) for
1 min, the samples were washed 2 times with ddH2O followed by a
staining with 2% aqueous phoshotungstic acid (SIGMA, St. Louis,
MO), pH 7.4 for 1 min. After that, the samples were visualized with
the electron microscope JEM1010 from JEOL and analyzed with
Digital Micrograph version 1.18.78 from Gatan Inc. USA.
Time of addition experiment
LLC-MK2 cells were seeded at 306104 cells/well in 6-well
plates. The cells were incubated with DENV-2 (500 pfu) at 4uC for
1.5 h on a rocking platform. The cells were then washed with cold
PBS(2) 3 times and the plates were shifted to a 37uC incubator
and cultured. During the time for viral adsorption and infection,
Curdlan Sulfate as an Efficient Entry Inhibitor for Dengue Virus
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plaque assay medium containing 100 mg/mL of either heparin
(MP Biomedicals, Solon, OH) or CRDS was added to the cells at
appropriate time points (21.5, 0, 1, 2, 3, 4 and 5 h) for 5 days.
Viral amounts were monitored by a plaque assay. Experiments
were conducted in triplicates and mean percentage inhibition was
calculated relative to control, which consists of the same set-up but
without inhibitors [39].
Cell fusion inhibition assay
This assay was used to detect the inhibition of cell fusion by test
compounds at low pH. C6/36 cells were seeded with a cell density
of 1.06106 cells/well in 6-well plates one day prior to the assay.
Dengue virus was inoculated at multiplicity of infection (MOI)
0.03 onto seeded C6/36 cells along with either 100 mg/mL of
heparin, CRDS, or medium with DMSO. Each set-up was then
incubated for 2 days at 28uC. Thereafter, the medium was
acidified to induce fusion by addition of 50 ml of 0.5 M 2-(N-
morpholino)ethanesulfonic acid (MES) (pH 5.0) (SIGMA, St.
Louis, MO), followed by incubation at 28uC for 2 days. Fusion
cells were then stained with Giemsa stain, modified solution
(SIGMA, St. Louis, MO) according to manufacturer’s protocol.
The stained plates were analyzed under the microscope [40–41].
Figure 1. Chemical structure of CRDS and antiviral activity based on DENV-2 MTT assay using LLC-MK2 cells. Structure of CRDS (A) and
dose-dependent inhibition of DENV-2 infection by CRDS by MTT assay (B).
doi:10.1371/journal.pntd.0002188.g001
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FACS analysis
Cells were fixed with 4% paraformaldehyde in PBS for 5 min
and treated with 0.5% saponin and 2% Fc-receptor blocking
solution (Human Trustain FcX, BioLegend, San Diego, CA) in
PBS(2) 4uC for 30 min. Immunostaining of the cells was
performed with the first antibody (1/10 dilution HB114) [42] at
4uC for 30 min followed by staining with the second antibody (1/
100 dilution goat anti-mouse IgG PE conjugated, SC-3738 Santa
Cruz Biotechnology, Santa Cruz, CA) at 4uC for 30 min. Cells
were analyzed with CyAn Flow Cytometer (Beckman Coulter,
Brea, CA).
ADE experiment
3H5 chimeric human/mouse IgG1 antibodies (h3H5) were
constructed and used as previously described [43]. Briefly,
0.391 mg/mL of h3H5 (ADE) or media (No antibody control)
was incubated with DENV-2 for 1 h at 37uC. CRDS was either
incubated with the immune complexes (pre-incubation) or after
immune complex formation (post-incubation), following which,
the mixture was added to THP-1 at MOI 10. After 24 h post-
infection, the cells were washed thrice in PBS, followed by RNA
extraction using RNAeasy kit (QIAGEN, Germantown, MD),
cDNA synthesis (Bio-Rad, Hercules, CA) and real-time qPCR
(Roche, Indianapolis, IN) according to the manufacturer’s




GAPDH primers were obtained from Origene and infection in
cells is expressed as units relative to GAPDH [44].
Anti-DENV assay in DC-SIGN-expressing cells
Raji/DC-SIGN+ (0.56106 cells/well) (a gift from Dr Timothy
Burgess) were infected with DENV (1000 pfu/mL) in the absence
or presence of the compound for 4 h at 37uC. The cells were
washed twice with medium to remove excessive virus and
incubated at 37uC in fresh culture medium. Raji/DC-SIGN+
cells were analyzed for DENV infection on day 4 after infection
[45].
Accession numbers
The Protein Data Bank (PDB) accession code for the DENV-2
Envelope protein used for the computational modeling in this
paper is 1OKE [13].
Results
DENV E protein binding potential of CRDS
The blind docking protocol (MVD) indicated that CRDS might
exhibit the potential to bind the DENV E protein. The binding
site of the CRDS molecule on the E protein was predicted to lie
near the fusion loop of the E protein monomer, at the interface of
the Domain II and Domain III of the E protein dimer
(Supplementary Fig. S1).
Identification of CRDS as an efficient DENV-2 inhibitor
The screening for anti-DENV activity was performed by the
conventional MTT assay using LLC-MK2 cells infected with
DENV-2 (Fig. 1B). The compound inhibited DENV-2 replica-
tion at concentrations starting as low as 0.1 mg/mL in LLC-
MK2 cells in a dose-dependent manner (Fig. 1B). CRDS
showed an EC50 of 7 mg/mL and a CC50 of more than 10 mg/
mL with LLC-MK2 cells. Thus, the selectivity index (ratio of
CC50/EC50) of CRDS was .1428, indicating that this
compound is both potent and selective. Control compound,
heparin, also showed a very potent anti-DENV activity with
EC50 of 0.5 mg/mL and a CC50 of more than 10 mg/mL in
the same experimental system.
The DENV can be propagated in broad range of host cells in
culture, which include cell lines of mammalian and insect origin.
The anti-DENV-2 activity of CRDS was further studied in
different cell lines. Non-adherent cells such as HL-60 and THP-
1, and adherent cells such as BHK-21 and C6/36 cells were
analyzed by MTT and FACS methods, respectively. The
efficient inhibitory effect of 100 mg/mL of CRDS on DENV
replication in HL-60 cells 4 days after infection is shown in
Fig. 2. CRDS was found to inhibit DENV-2 replication in all
cell lines studied at similar concentration range (data not
shown).
Structure-activity relationship of the CRDS
Some compounds analogous to CRDS were synthesized to
assess the structure-activity relationship against DENV-2 (Table 1).
Two CRDS analogs, CS0125 and CS0202, amongst 4 samples,
exhibited weak anti-DENV activity with an EC50 in the range of
0.2 mg/mL to 0.3 mg/mL, with no detectable cytotoxicity up to
5 mg/mL in LLC-MK2 cells.
CRDS inhibits all 4 serotypes of DENV
We investigated the activity of CRDS against three other
serotypes of DENV (DENV-1, 3 and 4). CRDS was found to be
active against all serotypes of DENV, with EC50 values of 0.262,
0.01 and 0.069 mg/mL against DENV-1, 3 and 4, respectively
(Table 2). Of all the DENV serotypes, DENV-1 appeared to be
less susceptible to CRDS. These data clearly showed that the
CRDS is effective against all four DENV serotypes, though the
extent of anti-DENV effect of CRDS is dependent on the
serotypes of the virus [46].
CRDS does not inhibit replication of DENV subgenomic
replicon
Based on our previous data showing that CRDS efficiently
inhibits the entry process of HIV, we presumed that this
compound might also act at the early stages of DENV replication.
To confirm that CRDS exerts its antiviral effect at the early step of
DENV life cycle and not at a later stage, the effect of the molecule
on the replication of DENV subgenomic replicon, encoding only
non-structural viral proteins, was studied in replicon-transfected
cells. Neither CRDS nor heparin inhibited replication of the
DENV subgenomic replicon in the luciferase activity assay,
whereas the replication inhibitor NITD008 [47] used as a control
showed significant inhibition of replication (Fig. 3A). To confirm
that CRDS indeed inhibits an early step of the fusion process,
LLC-MK2 cells were incubated with DENV-2 at 1,000 pfu with
or without various concentrations of CRDS at 37uC for 1.5 h. The
cells were then thoroughly washed and cultured without the
compound further for 4 days. The cells were then subjected to
FACS analysis. The results indicated that CRDS might suppress
the binding of DENV to host cells at all the three CRDS
concentrations used (Fig. 3B). The control compound, heparin,
inhibited this step similarly.
CRDS inhibits both attachment as well as an early post-
attachment step of entry
To identify the exact step of infection at which CRDS exerts its
inhibitory effect, we characterized the kinetics of compound
Curdlan Sulfate as an Efficient Entry Inhibitor for Dengue Virus
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activity using time of addition assays. We examined whether
CRDS blocked the initial attachment step in the LLC-MK2 cells,
or a downstream event in the viral entry process. When CRDS or
heparin was added together with DENV to cells during the 4uC
attachment step (21.5 h), and then removed prior to shifting to
37uC, both sulfated polysaccharides (100 mg/mL) could inhibit
DENV infection completely. Interestingly, CRDS blocked viral
infection almost completely even when it was added at the time of
temperature shift to 37uC (0 h) allowing viral entry and membrane
fusion to proceed. However, heparin inhibited DENV only by
about 50% under the same experimental conditions. CRDS was
then added at various time intervals up to 5 h post infection to
Table 2. Antiviral activity of CRDS on the four dengue virus
serotypes.
EC 50 (mg/mL) CC 50 (mg/mL) SI
DENV-1 0.262 .10.0 .38.2
DENV-2 0.007 .10.0 .1428
DENV-3 0.010 .10.0 .1000
DENV-4 0.069 .10.0 .144.9
doi:10.1371/journal.pntd.0002188.t002
Figure 2. Efficient inhibitory effect of CRDS on DENV replication in monocytic HL-60 cells. Anti-DENV-2 was monitored at 100 mg/mL of
CRDS 4 days after infection in HL-60 cells.
doi:10.1371/journal.pntd.0002188.g002
Table 1. Structure-activity–relationship of the CRDS.
Sample ID [a]25Da, deg Mn
b61024 Elem, anal., % DSc EC50d (mg/mL) CC50e (mg/mL) SIf
C S H
CS11303d 20.6 0.4 21.5 3.3 13.5 1.2 - 1.41 -
CS1221 +1.3 0.7 25.5 3.9 10.7 0.8 - 7.51 -
CS0125 +0.3 1.4 19.9 3.4 14.7 1.4 0.26 7.94 30.5
CS0202 22.5 0.6 19.2 2.9 15.0 1.5 0.37 5.32 14.0
CRDS 0.0 4.1 21.8 3.3 11.5 0.9 0.007 .10.0 .1428
a: Measured in H20.
b: Molecular weight.
c: Degree of sulfation.
d: 50% effective concentration.
e: 50% cytotoxic concentration.
f: 50% cytotoxic concentration/50% effective concentration.
doi:10.1371/journal.pntd.0002188.t001
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Figure 3. Failure of CRDS to inhibit viral replication in DENV subgenomic replicon cells. Fig. 3 A) The effect of the CRDS and control
molecules, NITD 008, on the replication of DENV subgenomic replicon, encoding only non-structural viral proteins, was measured by luciferase
activity assay in replicon-transfected cells. The replication inhibitor NITD008 [46] was used as a positive control. Fig. 3 B) CRDS inhibits an early step of
the fusion process. The LLC-MK2 cells were incubated with DENV-2 at 1000 pfu with or without various concentrations of CRDS concentration at 37uC
only for 1.5 h. After the viral adsorption, the cells were thoroughly washed and cultured without the compound further for 4 days. The cells were then
subjected to FACS analysis.
doi:10.1371/journal.pntd.0002188.g003
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address the kinetics of CRDS activity. The results demonstrated
that inhibition was only seen by 0 h but not after infection,
confirming its point of action during DENV entry/membrane
fusion. Hence, heparin was only effective in preventing entry when
added during the viral attachment step while the CRDS was also
effective even during the post-attachment stage (Fig. 4A, B). Taken
together, the data suggest that CRDS can block an event in
DENV entry that lies temporally downstream of attachment to
cells, either before or during fusion.
Alkyl CRDS-coated membrane filter adsorbs DENV-2
Ten-fold dilutions of virus solutions were prepared in 24-well
plates. The alkyl CRDS-coated membrane filter (one or three
sheets) was then placed in the wells. After 5 min, each solution
(500 mL) was removed from the plate and transferred to another
24-well plate, and viral titers were monitored as described in
Materials and Methods. The DENV titers were reduced by more
than 70% when viruses were treated with membrane filters coated
with alkyl CRDS (2.0 mg) as compared to those with membrane
Figure 4. CRDS inhibits both attachment as well as an early post-attachment step of entry. Time of addition experiments were performed
to identify the step at which CRDS exerts its effect (A) and efficacy of inhibitors during attachment and post-attachment (B). Studies were performed
using the LLC-MK2 cells as described in Materials and Methods in detail.
doi:10.1371/journal.pntd.0002188.g004
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filters without alkyl CRDS, showing that the viruses were adsorbed
more efficiently to CRDS-coated membrane (Fig. 5A).
CRDS possibly binds directly to the DENV
DENV were mixed with CRDS for 1 h at 4uC and then, viral
particles were separated with a Vivaspin 500 to monitor viral titer
by plaque assay. The results showed that DENV titer was reduced
to about 60% of control level which was treated with PBS. Hence,
direct binding of DENV to CRDS was suggested (Fig. 5B).
CRDS causes viral aggregation and changes to the
surface of DENV-2 virus upon interaction
Electron microscopy (EM) was used to visualize the effect of the
CRDS on DENV-2 viral particles. We noticed that the treated
Figure 5. Analysis of CRDS interacted with dengue virus particles. Concentrated DENV-2 was incubated with or without CRDS, and the
supernatant was then analyzed for infectivity by plaque assay (A and B) or EM (C). A) Virus incubated with or without CRDS-coated membrane. B)
Virus incubated with or without CRDS in PBS. C) Virus incubated with or without CRDS in PBS. There are significant differences in the infectivity
between supernatants of virus treated with and without CRDS (p,0.0001) (A and B).
doi:10.1371/journal.pntd.0002188.g005
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DENV virions were visible as aggregates while control dengue
virions were found mainly as solitary particles. Also, while control
virions exhibited the normal, nearly smooth, outer surface typical
of mature flaviviruses, the surface of the CRDS-treated virus
particles seemed to be rougher, implying a possible structural
change of the viral envelope (Figure 5C).
CRDS inhibits cell-to-cell infection/spread of DENV
Cell-to-cell transmission, in addition to cell-free virus infection,
is considered to be the key mechanism of spread of DENV
infection, although syncytia formation does not necessarily
indicate virus spread. Flavivirus induces cell fusion very efficiently
upon infection in Aedes albopictus C6/36 cells at low pH. When C6/
36 cells were incubated with DENV at 4uC for 1.5 h during viral
adsorption in the presence of 100 mg/mL of either CRDS or
heparin followed by culture for 4 days at 28uC, the appearance of
fused cells was completely blocked by both compounds (Fig. 6A).
Consistent with the time of addition studies, CRDS inhibited
syncytia formation even when it was added at the time of
temperature shift to 28uC, whereas significant syncytia formation
was observed in the cells treated with Heparin (Fig. 6B).
We also carried out the co-culture experiments of naı¨ve C6/36
cells with 2 day-old DENV infected C6/36 cells in the presence or
absence of CRDS for 2 days to observe its effect on syncytium
formation. The compound completely blocked the appearance of
DENV-induced fused cells (data not shown).
CRDS can block ADE of DENV infection
The observation that CRDS prevents virus binding to the host
cell surface prompted us to evaluate whether this compound can
also exert an antiviral effect towards DENV particles pre-
opsonized with antibodies, in THP-1 cells. For this purpose, the
infectious properties of DENV particles pre-opsonized with
increasing concentrations of antibody was determined in the
presence of 1 mg/mL of CRDS. The antibody enhanced DENV
infectivity by 4 times in THP-1 cells as compared to control
Figure 6. Effect of CRDS on low pH-induced fusion of DENV-2 infected C6/36 cells. The cells were incubated with DENV at 4uC for 1.5 h
during viral adsorption in the presence of 100 mg/mL of either CRDS or heparin, followed by a temperature shift to 28uC, and cultured for 4 days to
monitor virus-induced cell fusion (A). In the experiment shown in B, the compound was added at the time of temperature shift to 28uC, after viral
attachment.
doi:10.1371/journal.pntd.0002188.g006
Figure 7. Effect of CRDS on anti-DENV-2 antibody-enhanced
infection of THP-1. The effect of CRDS on infectious properties of
DENV particles pre-opsonized with enhancing concentrations of
antibody was determined. Anti-ADE effect of CRDS (1 mg/mL) was
tested by either simultaneous treatment of DENV with CRDS before
addition of antibody or after mixing of virus and antibody [ADE with
CRDS (late)].
doi:10.1371/journal.pntd.0002188.g007
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without the antibody. Under this condition, CRDS prevented
more than 70% ADE when the simultaneous treatment of DENV
with CRDS was done, before the addition of antibody. Also,
nearly 60% inhibition was seen even when treatment was
performed after mixing of virus and antibody concurrently
(Fig. 7, ADE with CRDS (late)).
Effect of CRDS on DENV-2 infection in DC-SIGN-
expressing cells
We also evaluated the effect of CRDS on DENV infection in
DC-SIGN expressing Raji-DC-SIGN cells. Cells were infected
with a large concentration of DENV (1,000 pfu) in the presence of
CRDS. The cultures were analyzed for DENV infection by FACS
analysis 4 days later. CRDS inhibited DENV infection in these
cells rather weakly but significantly (by only about 10–15%) at a
concentration of 100 mg/mL (Fig. 8).
Probable binding model of CRDS to DENV envelope
protein
To further specify the possible protein-ligand interactions and to
model the conformational changes of the protein brought about by
binding of the inhibitor, a flexible receptor docking study was
performed. The receptor and ligand were both docked flexibly, in
order to obtain the docking pose with the least entropy possible, as
would be the case in vitro. The Chemscore based docking algorithm
of Glide module (Schrodinger Suite 2012) imposes constraints
based on rewarding of hydrogen bonding and hydrophobic
interactions, and penalization of steric clashes, followed by
minimization of energy due to non-bonded interactions based on
OPLS-aa force field.
The induced fit docking procedure produced five minimized
binding poses of the CRDS to the E Protein. Rank-ordering of
poses was done based on Glide Score, and the best scoring pose
is presented here as the most probable and optimal binding
model of CRDS to the DENV E protein. This model predicted
that CRDS binds to the E protein at the DII and DIII-DI
interface of the two monomers. The proposed model also
indicated that the CRDS fits at one end, in a pocket below the
flexible ‘kl’ loop lining the hydrophobic cavity, described as the
BOG binding pocket by previous research (Fig. 9). The tail end
of the CRDS interacts with residues that neighbor the fusion
loop (DII – residues 100–108).
The H-bonding interaction map of the CRDS at the binding
site revealed that the ligand forms hydrogen bonds with the two
conserved residues His 244 and Lys 310 (both 100% conserved
Figure 8. Effect of CRDS on DENV-2 infection in DC-SIGN-expressing cells. The effect of CRDS was evaluated on DENV infection in DC-SIGN
expressing cells. Raji-DC-SIGN cells were infected with large amount of DENV (1000 pfu) in the presence of CRDS. The cultures were analyzed for
DENV infection by FACS assays 4 days later.
doi:10.1371/journal.pntd.0002188.g008
Figure 9. Proposed binding model of CRDS to DENV envelope protein obtained by Induced fit docking. The coordinates of the DENV E
protein were obtained from PDB from the crystal structure 1OKE [13]. Detailed information is described in Materials and Methods.
doi:10.1371/journal.pntd.0002188.g009
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across all DENV serotypes) and Asn 153 and Lys 247 (80%
conserved), apart from other residues (Table 3, Fig. 10A, B)
[48].
The LigPlot map [49] of the CRDS-E protein docking model
indicated hydrophobic interactions (Fig. 11) with Trp 101, Asn
103, His 244 (all 100% conserved residues), and Gly 28 (80%
conserved) [48].
The RMSD deviation of the docked pose of the protein
obtained by induced fit, when compared to the conformation of
the crystal structure, was found to be 0.14 A˚, following pairwise
alignment. The per residue RMSD revealed the highest deviation
to be that of Lys 157(B), at 5.69 A˚, followed by Arg 2 (B), which
was 2.91 A˚.
Discussion
As do the other viral envelope proteins, the DENV E protein
plays a crucial role in both binding of the virus particle to host cell
receptors and fusion of the viral membrane with the target
membrane. Hence, the E protein is one of the more attractive
targets to inhibit DENV entry, to develop novel anti-viral drugs, as
well as to discover effective vaccines. In this paper, we report that a
sulfated 1R3- b -D glucan, CRDS, inhibits entry and fusion steps
of the DENV life cycle very efficiently in several different cells of
mammalian and mosquito origin. CRDS is very potent and
selective since its minimal effective concentration is as low as
0.1 mg/mL in LLC-MK2 cells while toxicity is only seen at the
Figure 10. Hydrogen bonding interactions of the inhibitor with the residues in the binding pocket. Strong H-bonds (Table 3) are formed
with conserved residues His 244, Lys 310, Asn 153 and Lys 247 (A). Residues lining the CRDS-binding pocket of the E protein (B).
doi:10.1371/journal.pntd.0002188.g010
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concentrations more than 10 mg/mL. Although the anti-viral
activity was comparatively weaker, it is important to note that
CRDS could also inhibit DENV-1, 3, and 4.
DENV-2 and DENV-3 infections are very efficiently inhibited,
whereas DENV-1 and DENV-4 infections require much higher
concentration of the compound to achieve inhibition. The results
of the experiments on anti-DENV effect of polysaccharides with
different serotypes of the DENV obtained by Talarico et al. and
Pujol et al. correlate with our results [46,50]. This phenomenon is
most probably not related to the difference in amino acid sequence
of the E protein. Wang et al. derived a phylogenetic tree from the
comparison of the DENV E gene nucleotide sequence, where they
put forth that DENV-1 and DENV-3 are sister groups [51]. We
believe that this difference could be due to the differences in the
internalization/endocytosis pathway of the DENV particle of
different serotypes. DENV utilizes different pathways for entry in
different cells, and for that matter, even in the same cell type. In
fact, distinct receptors have been proposed for different serotypes
in the same host cells [52,53].
Our results do indicate that CRDS inhibits the virus binding to
the host cells, and also pH dependent cell fusion. The mechanism
by which CRDS prevents virus binding is most probably by
inhibition of virus internalization into the host cells via endocy-
tosis. However, endocytosis of the virus particle may occur by any
of the mechanisms, viz., phagocytosis, macropicnocytosis, clathrin-
mediated endocytosis or caveolin-mediated endocytosis. We don’t
have evidence that CRDS can inhibit endocytosis by any or all of
these routes. However, it could be that the DENV-CRDS complex
undergoes internalization into the host cell. But the presence of
CRDS prevents the viral fusion with the host vesicular membranes
and thus inhibits the release of viral genome into the host
cytoplasm. The vesicle is probably then degraded.
From the anti-viral therapeutic point of view, sulfated polysac-
charides are compounds of particular interest because they have
been shown to exhibit potent entry inhibitory activity against
diverse viruses such as HIV, CMV, VSV, and HSV [54,55,56]. As
expected, while CRDS did inhibit the early step of DENV
infection, it failed to inhibit the replication of DENV subgenomic
replicon. Time of addition experiments demonstrated that the
compound inhibited viral infection at an early step of DENV
infection. Although heparin showed similar activity, there are
apparent differences in the activities of CRDS and heparin; CRDS
inhibits both viral binding to cells and an early post-attachment
step of entry (membrane fusion), while heparin acts mainly at the
virus binding step. Our finding that CRDS inhibits cell-to-cell
infection/spread of DENV more efficiently than heparin, is also
consistent with our proposal that CRDS also inhibits membrane
fusion between the host cell and the viral envelope.
DENV attachment to host cells has been proposed to be
mediated by the binding of receptor glycosaminoglycans (GAGs)
to the DIII of the E protein [57]. Two putative receptor GAG
binding motifs have been mapped to the DIII [57,58]. Abd-Jamil
et al. proposed that while the GAG binding motif of loop I could
mediate the E protein interaction with the host cell GAG, the
residues on loop II could mediate a later, more receptor-specific
interaction to facilitate virus attachment [58].
We investigated the possibility of direct binding and interaction
of CRDS to DENV particles by 3 different approaches; virus
titration after either mixing of DENV with CRDS followed by
Vivaspin 500 or adsorption of DENV-2 to alkyl CRDS-coated
membrane filter, and EM studies. Both procedures showed that
the DENV titer was reduced to less than 30% of control level
which was treated with PBS, suggesting direct binding of CRDS to
DENV (Fig. 5A, B). Recently, two of the co-authors of this paper
(TM and TY) showed that the alkyl CRDS-coated membrane
filter was found to have a specific adsorptive functionality for
influenza A, but not B, virus in vitro [38]. However, the membrane
filter without the compound did not effectively remove Influenza
viruses, and thus a membrane filter without alkyl CRDS was not
effective against Influenza viruses. These results, taken together
with ours, strongly suggest that the alkyl CRDS-coated membrane
filter removed DENV and influenza A viruses by interactions
between the negatively charged sulfate groups and the positively
charged envelope proteins of both viruses. Therefore, it is likely
that CRDS might recognize DENV through specific interaction
with the surface glycoproteins of the DENV. The detailed
adsorptive mechanism requires further investigation.
The above interpretation was further supported by EM, which
was used to visualize the effect of the CRDS on DENV-2 viral
particles. CRDS apparently induced aggregation of DENV virions
by possible alteration of viral surface. As compared to control
virions that exhibited the normal, nearly smooth, outer surface
which are typical for mature Flaviviruses, the surfaces of the
CRDS-treated virus particles seemed to be rougher, implying a
possible manipulation of the viral envelope (Figure 5C). This
observation is reminiscent of the recent report by Costin et al. [59]
wherein it was demonstrated, using biolayer interferometry and
cryo-electron microscopy respectively, that the anti DENV-2
peptides, which were newly developed, interfere with viral binding
to cells through direct interaction with the E proteins, eventually
leading to changes of the viral surface. Thus, it is possible that, like
these peptides, CRDS can trap the viral E proteins in some
conformational arrest which is not suitable for viral binding to cells
and entry.
According to the binding model proposed by us here, CRDS
forms strong H bonds with Lys 310, a residue that is 100%
Table 3. The H-bonding interactions of the CRDS with the
residues of the E protein.
H bond Donor H bond Acceptor Distance (A˚)
Lig:OH ND1:His244(A) 2.7
(A)Lys246:NZ1 O: Lig 2.1
(A)Lys247:NZ O: Lig 2.4
Lig:OH O:Gly275(A) 1.7
Lig:OH O:Gly275 (A) 2.0










(B)Lys310:NZ O: Lig 1.8
(B)Lys310:NZ O: Lig 2.1
(B)Arg 323: NH2 O: Lig 1.6
(B)Arg323: NH1 O: Lig 2.2
(B)Arg323: NH1 O: Lig 2.2
doi:10.1371/journal.pntd.0002188.t003
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conserved among the flaviviruses [48], which is also a part of the
GAG binding motif of loop I. The proximity of the loop I residues
to the fusion peptide, near which the CRDS molecule is proposed
to bind, in the dimer conformation of the E protein, could also
mean that the ability of the loop I residues to form substantial
interactions with the host cell surface GAG moieties will be
hindered. This looks particularly plausible in view of the fact that
the actual CRDS molecule is lengthier and spans more of the
dimer surface than can be analyzed by Induced Fit, due to the
limitation on the number of atoms of the ligand molecule specified
by the software. The Structure-activity-relationship (SAR) of
CRDS was studied based on its anti-DENV2 activity by
synthesizing 4 analogues with various degrees of molecular weights
as well as different chemical compositions (Table 1). The anti-HIV
activity of CRDS is dependent on not only the degree of sulfation
but also on the molecular weight of the molecules [24]. In our
experiment, CRDS showed much higher anti-DENV activity as
compared to the two CRDS analogues, CS0125 and CS0202,
Figure 11. LigPlot+ representation of the hydrophobic interactions between CRDS and the residues of the binding pocket. The
hydrophobic contacts are represented by dotted lines. The LigPlot+ [49] was used to map the interactions.
doi:10.1371/journal.pntd.0002188.g011
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both with higher extent of sulfation, but lower molecular weight
than CRDS. Hence, it is possible that molecular weight is
important for the anti-DENV activity of CRDS. However, since
we did not test sulfated polysaccharides with molecular mass
greater than that of CRDS, more extensive studies are essential to
draw a conclusion to that effect. The possible mechanism of
inhibition of the virus – host membrane fusion process by CRDS
could be explained by the steric hindrances and non-covalent
ligand-protein interactions, as predicted by the flexible receptor-
ligand docking. CRDS is predicted by our Induced fit docking
protocol to bind in the proximity of the previously described BOG
binding pocket beneath the kl hairpin. The kl hairpin, comprising
residues 268–280, has been described to play a key role in the
conformational changes driving the transition of the E protein
from the dimer form to the fusion competent trimer form. Modis
et al. proposed that a shift in the position of the kl loop towards the
interface between DI and DII of the dimer partners causes the DII
to swing away from its dimer contact and thus project the fusion
peptide at its distal tip towards the host membrane for fusion [21].
In our proposed model for CRDS binding, it is seen that the
ligand forms hydrogen bonds with Gly 275, and hydrophobic
interactions with Asn 276, both residues of the kl hairpin. These
interactions coupled by the steric hindrance offered by the physical
presence of the CRDS molecule at the DI-DII interface of the
dimeric partners of the E protein could very well prevent the
shifting motion of the kl hairpin said to be the initiating action for
the dimer-trimer transitions.
Modis et al. [21] also proposed a post-fusion conformation
model of the DENV E protein, describing the conformational
changes required to effect the trimerization. Here, they proposed
that the kl hairpin shift causes the DII to undergo a 30u rotation
with respect to DI of the E monomer, followed by a 70u rotation of
DIII, corresponding to a 36 A˚ shift towards DII. Our model of
CRDS binding indicates that the occupation of the space at the
dimer interface by CRDS molecule will offer steric hindrance to
the movement of DIII and prevent its rotation, thus preventing the
trimerization process.
One of the more significant observations from our experiments
is the ability of CRDS to inhibit ADE-mediated DENV infection
in THP-1 cells expressing Fc receptor. As is well appreciated, ADE
is thought to be the major cause of DHF/DSS, and fear of
inducing ADE has hampered the development of a DENV vaccine
[60]. Based on our observations, it is important to address whether
CRDS indeed can block ADE in mice before moving on to human
subjects to explore the possibility for it to serve as a candidate for
clinical trials for the treatment of DENV infections.
At early stages of infection, the virus is said to replicate in DC-
SIGN-positive cells [61]. DC-SIGN is considered to be a critical
receptor for DENV, because it renders non-permissive cells
susceptible for DENV infection and DC-SIGN is highly expressed
in immature DC [62–64]. Though immature DCs are still not
functional, they are equipped with receptors that mediate
attachment, such as DC-SIGN, to capture diverse pathogens.
DC-SIGN preferentially recognizes high-mannose sugars. Our
study details the inhibitory effect of CRDS on DENV infection of
DC-SIGN expressing cells. This points to the possibility that
therapeutic application of CRDS can be effected in the early
stages of DENV infection.
In the possible use of sulfated polysaccharides clinically, one of
the concerns is about their anti-coagulant activity. The application
of heparin, especially in its systemic use, has been associated with
apparent anti-coagulant activity. Though CRDS is also a
polyanionic substance like heparin, it is largely devoid of
anticoagulant potential [23]. CRDS has been shown to be
effective against HIV-1, Plasmodium falciparum in vitro [65], and
Babesia infections [66]. The anticoagulant activity of CRDS in
humans is also well documented in clinical trials on HIV patients
[67,68] and in studies on asymptomatic malaria patients [26]. The
dosage of CRDS given to patients could be higher than that of
heparin. Though results obtained in trials on HIV-infected
patients were disappointing in terms of the efficacy, this could
be due to the chronic nature of the disease as well as the HIV,
which requires that CRDS be administered continuously to
suppress viral activity. However, in case of cerebral malaria, upon
CRDS treatment, disease symptoms such as fever, coma and
organ involvement were delayed relative to parasite clearance and
resulted in the favourable immune response [26]. Any effect on
coagulation with prolonged usage of CRDS can be monitored
easily, with subsequent adjustment of dosage. However, since
DENV infection is notoriously associated with hemorrhage,
DENV-infected patients should be monitored with additional
care to note the effect of CRDS on coagulation time.
In conclusion, CRDS acts by interfering with the viral binding
and membrane fusion steps, early and critical events of virus
replication in DENV infection. We propose that the CRDS
molecule binds to the DENV E protein at the DI-DIII and DII
interface of the dimer partners. Since CRDS is well tolerated in
clinical trials for HIV and cerebral malaria, further in vivo and
clinical studies are warranted.
Supporting Information
Figure S1 Binding of CRDS to DENV E protein predicted by
blind docking using the MVD program.
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